{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.55","upperLimit":"8.57","value":"6.97"},{"groupId":"OG001","lowerLimit":"11.99","upperLimit":"29.01","value":"19.32"},{"groupId":"OG002","lowerLimit":"7.00","upperLimit":"11.50","value":"9.53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"246"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as the time from the start date of study drug to the date of the first radiologically documented progressive disease (PD) per RECIST 1.0. or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with ALK-translocated NSCLC who were previously treated with an ALK inhibitor.","id":"OG000","title":"NSCLC With Prior ALKi (Arms 1A + 1B)"},{"description":"Patients with ALK-translocated NSCLC not previously treated with an ALK inhibitor","id":"OG001","title":"NSCLC ALKi Naive (Arm 2)"},{"description":"all NSCLC patients.","id":"OG002","title":"ALL NSCLC"}],"paramType":"MEDIAN","populationDescription":"Full analysis set (FAS) - NSCLC: Subset of Full Analysis Set including ALK-positive NSCLC patients who received at least one dose of LDK378 in the 750 mg dose group.","reportingStatus":"POSTED","timeFrame":"275 weeks","title":"Progression-free Survival Based on BIRC Assessment","type":"SECONDARY","unitOfMeasure":"months"}